✦ LIBER ✦

Dacarbazine and fotemustine in advanced colorectal cancer

✍ Scribed by Tixi, L.; Bolli, E.; Guglielmi, A.; Mori, A.; Aschele, C.; Nobile, M.T.; Rosso, R.; Sobrero, A.

Book ID: 123234344
Publisher: Elsevier Science
Year: 1993
Tongue: English
Weight: 141 KB
Volume: 29
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(93)90409-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination of dacarbazine and mitomycin

Combination of dacarbazine and mitomycin in advanced colorectal cancer

✍ H. Bleiberg; M. Clavel; C. Nicaise; J. Devriendt; J. Michel; B. Vanderlinden; M. 📂 Article 📅 1982 🏛 Springer 🌐 English ⚖ 237 KB

Fotemustine plus dacarbazine in advanced

Fotemustine plus dacarbazine in advanced stage III malignant melanoma

✍ Binder, Michael; Winkler, Alexander; Dorffner, Roland; Glebowski, Eva; Wolff, Kl 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 389 KB

Phase II trial of fotemustine in advance

Phase II trial of fotemustine in advanced colorectal cancer

✍ Bleiberg, H.; Becquart, D.; Michel, J.; Cavalli, F.; Gerard, B. 📂 Article 📅 1990 🏛 Elsevier Science ⚖ 297 KB

Fotemustine and dacarbazine plus recombi

Fotemustine and dacarbazine plus recombinant interferon alpha2a in the treatment of advanced melanoma

✍ P Comella; A Daponte; R Casaretti; F Ionna; F Fiore; F Presutti; G Frasci; F Cap 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 521 KB

Phase III randomized study of fotemustin

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

✍ Antonio Daponte, Simona Signoriello, Luigi Maiorino… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 445 KB

Combination of dacarbazine, mitomycin C,

Combination of dacarbazine, mitomycin C, 5-fluorouracil and vincristine in advanced colorectal cancer

✍ Geoffrey Falkson; H. L. Pretorius; H. C. Falkson; H. S. Schoeman 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 137 KB

Thirty patients with advanced measurable colorectal cancer received monthly courses of a combination of dacarbazine, mitomycin C, 5-fluorouracil, and vincristine (FIVMit-Or). Four of the patients had received prior chemotherapy. Two patients were not evaluable for response. Objective response was ob